Furthermore, the latest study showed that the overexpression of CCNE1 in HER2 positive tumor can impair the anti-HER2 therapy through resulting in resistance to trastuzumab both in vitro and in vivo, whereas the mechanisms leading to CCNE1 over-expression in these cells are unclear [56]. This evidence concerns the gene ERBB2 and neoplasm.